Role of Transforming Growth Factor-β1 Gene Polymorphisms in Childhood Idiopathic Thrombocytopenic Purpura

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 11, 2003, Pages 885-889

  Atabay, Berna ^a   Ören, Hale ^a   Irken, Gülersu ^a   Kizildaǧ, Sefa ^a   Tunali, Sunay ^a   Türker, Meral ^a   Yilmaz, Şebnem ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Gene polymorphism; Idiopathic thrombocytopenic purpura; Thrombocytopenia; Transforming growth factor 1

Indexed keywords

GENOMIC DNA; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ARTICLE; CHILD; CODON; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFANT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CODON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; MALE; POLYMORPHISM, GENETIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0242524450     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200311000-00012     Document Type: Article

References (31)

1. Imbach P. Immune thrombocytopenic purpura. In: Lilleyman J, Hann I, Blanchette V, eds. Pediatric hematology. London: Churchill Livingstone; 1999:437-453.
2. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40.
3. Castro V, Oliveira GB, Origa AF, et al. The human platelet alloantigen 5 polymorphism as a risk for the development of acute idiopathic purpura. Thromb Haemost. 2000;84:360-361.
4. Nomura S, Matsuzaki T, Ozaki Y, et al. Clinical significance of HLA-DRB*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood. 1998;91:3616-3622.
5. Kaplan C, Morinet F, Carton J. Virus-induced autoimmune thrombocytopenia and neutropenia. Semin Hematol. 1992;29:34-44.
6. Kim TG, Kim HY, Lee SH, et al. Systemic lupus erythematosus with nephritis in strongly associated with the TNFB*2 homozygote in the Korean population. Hum Immunol. 1996;46:10-17.
7. Sullivan KE, Wooten C, Schmekpeper BJ, et al. A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus crythematosus in African-Americans. Arthritis Rheum. 1997;40:2207-2211.
8. Keen RW, Woodford-Richens K, Lanchburry JS, et al. Allelic variation at interleukin-1 receptor antagonist gene in associated with early postmenapausal bone loss at the spine. Bone. 1998;23:367-371.
9. Pociot F, Ronningen KS, Bergholdt R, et al. Genetic susceptibility marker in Danish patients with type 1 (insulin dependent) diabetes-evidence for polygenicity in man. Autoimmunity. 1994;19:169-178.
10. Louis E, Satsangi J, Roussomoustakaki M, et al. Cytokine gene polymorphisms in inflamatory bowel disease. Gut. 1996;39:705-710.
11. Epstein H, Blobe GC, Schieman WP, et al. Role of transforming growth factor-β in human disease. N Engl J Med. 2000;11:133-145.
12. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Reev Immunol. 1998;16:137-161.
13. Prudhomme GJ, Piccirillo CA. The inhibitory effects of transforming growth factor-beta-1 in autoimmune disease. J Autoimmunol. 2000;14: 23-42.
14. Sakamaki S, Hirayama Y, Matsunaga T, et al. Transforming growth factor-β1 (TGF-β1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-β1 receptor on megakaryocytes and in turn renders them susceptible to suppression by TGF-β1 itself with high specificity. Blood. 1999;94:1961-1970.
15. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet. 1999;8:93-97.
16. Awad MR, El-Gamel A, Hasleton P, et al. Genotypic variation in the transforming growth factor-β1 gene: association with transforming growth factor-β1 production, fibrotic lung disease and graft fibrosis after lung transplantation. Transplantation. 1998;66:1014-1020.
17. Li B, Khanna A, Sharma V, et al. TGF-β1 DNA polymorphisms, protein levels, and blood pressure. Hypertension. 1999;33:271-275.
18. Yamada Y, Miyauchi A, Takagi Y, et al. Association of the C-509→T polymorphism, alone or in combination with the T869→C polymorphism, of the transforming growth factor-β1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women. J Mol Med. 2001;79:149-156.
19. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40.
20. Fujimura K, Takafuta T, Kuriya S, et al. Recombinant human interferon alpha 2b (rHIFN alpha 2b) therapy for steroid resistant idiopathic thrombocytopenic purpura (ITP). Am J Haematol. 1996;51:37-44.
21. Thude H, Gatzka E, Anders O, et al. Allele frequencies of human platelet antigen 1,2,3, and in normal people. Vox Sang. 1999;77:149-153.
22. Karpatkin S, Fotino M, Gibofsky A, et al. Association of HLA-Drw2 with autoimmune thrombocytopenic purpura. J Clin Invest. 1979;63:1085-1088.
23. Fujimoto TT, Inoue M, Shimomura T, et al. Involvement of Fcγ receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. Br J Haematol. 2001;115:125-130.
24. Foster CB, Shaoxian Z, Erichsen HC, et al. Polymorphisms in inflammotory cytokines and Fcγ reseptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Br J Haematol. 2001;113:596-599.
25. Cines DB, Blanchette VS, Chir B. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
26. Kim BS, Song KS. Genetic polymorphism of human platelet specific antigen (HPA) in patients with immune thrombocytopenia. Thromb Haemost. 1997 (suppl):PS1037.
27. Yamada Y, Miyauchi A, Goto J, et al. Association of a polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res. 1998; 13:1569-1576.
28. Andersson PO, Stockelberg D, Jacobsson S, et al. A transforming growth factor β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol. 2000;79:507-513.
29. Cambien F, Ricard S, Troesch A, et al. Polymorphism of the transforming growth factor-β1 gene in relation to myocardial infarction and blood pressure. Hypertension. 1996;28:881-887.
30. Syrris P, Carter ND, Metcalfe JC, et al. Transforming growth factor-β1 gene polymorphisms and coronary artery disease. Clin Sci. 1998;95:659-667.
31. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-β in blood: a complex problem. Cytokine Growth Factor Rev. 2000;11:133-145.